NCT03377413 is a clinical trial in Resting Energy Expenditure, sponsored by Peking University First Hospital.

Who is sponsoring NCT03377413?

NCT03377413 is sponsored by Peking University First Hospital.

What condition does NCT03377413 study?

NCT03377413 studies Resting Energy Expenditure, Chronic Kidney Disease.

Is NCT03377413 still recruiting?

NCT03377413 is currently completed. Last updated 14 October 2020.

Last reviewed 2020-10-14 · How we verify

NCT03377413

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Equation for Estimating Resting Energy Expenditure

Completed Last updated 14 October 2020

What this trial tests

trial in Resting Energy Expenditure in 300 participants. Completed in 1 February 2020.

Timeline

14 December 2017

Primary endpoint
31 January 2020

1 February 2020

Quick facts

Lead sponsor	Peking University First Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	14 December 2017
Primary completion	31 January 2020
Estimated completion	1 February 2020
Sites	1 location across China

Conditions studied

Resting Energy Expenditure — all drugs for Resting Energy Expenditure →
Chronic Kidney Disease — all drugs for Chronic Kidney Disease →

Sponsor

Peking University First Hospital

Who can join

Adults 18 to 80, any sex, with Resting Energy Expenditure or Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The energy and nutrition states are closely associated with CKD patients complications and outcomes.To reach the energy balance target, we need the accurate resting energy expenditure level of patients. Traditional equations are not applicable to CKD patients,so we aim to develop and validate a equation for estimating resting energy expenditure in CKD patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Novel equation for estimating resting energy expenditure in patients with chronic kidney disease.
Xu X, Yang Z, Ma T, Li Z, et al · · 2021 · cited 11× · PMID 33693520 · DOI 10.1093/ajcn/nqaa431
Association of Serum Adipokines and Resting Energy Expenditure in Patients With Chronic Kidney Disease.
Abi N, Xu X, Yang Z, Ma T, et al · · 2022 · cited 5× · PMID 35369060 · DOI 10.3389/fnut.2022.828341
Association of Serum Adipokines and Resting Energy Expenditure in Patients with Chronic Kidney Disease
Abi N, Xu X, Yang Z, Ma T, et al · · 2022 · DOI 10.21203/rs.3.rs-1208032/v1

Verify or expand the search:

Other recruiting trials for Resting Energy Expenditure

Currently open trials in the same condition.

NCT06575101 — Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management · recruiting
NCT06483542 — Bionenergetic Balance During CVVH · active not recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03377413 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 14 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03377413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing